Industry News

Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas

05/08/2025

Multicenter study sponsored by SELNET to evaluate cirtuvivint as a second-line monotherapy in selected sarcoma subtypes Excerpt from the Press Release: SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases, today announced…

Join The TrialStat Team in Bethesda, Maryland at the Clinical Outsourcing Group DMV Meeting!

05/06/2025

TrialStat will be showcasing our cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the COG DMV meeting in Bethesda, Maryland on May 13th – 14th. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing clinical research and streamlining clinical trial execution for Sponsors and CROs. Meet with…

Element Science Receives FDA Approval for the Revolutionary Jewel® Patch Wearable Cardioverter Defibrillator

05/05/2025

Groundbreaking device sets new standard in the management of patients with an elevated risk of sudden cardiac arrest Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–In a significant leap forward in the care of patients with cardiac disease, Element Science is proud to announce that its innovative Jewel® Patch Wearable Cardioverter Defibrillator (Patch-WCD) has received…

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

05/01/2025

Excerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months…

BriaCell’s Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3

04/24/2025

Excerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, April 10, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), are pleased to announce that BriaPro is developing novel,…

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

04/23/2025

Excerpt from the Press Release: PALO ALTO, Calif., April 16, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, following the formation of its proposed joint venture with IPMC Company,…

Join The TrialStat Team in Burlington, Massachusetts at the Clinical Outsourcing Group New England Meeting!

04/22/2025

TrialStat will be showcasing our cutting-edge EDC Platform with integrated Medical Imaging Platform at the COG New England Meeting in Burlington, Massachusetts on April 28th – 30th. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing clinical research and streamlining clinical trial execution for Sponsors and CROs. Meet with…

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 – a Novel IRAK4 Degrader for Inflammatory Conditions

04/22/2025

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in inflammation, in both rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis Nurix to receive a $5 million milestone payment from…

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

04/17/2025

CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress Dr. Arshed Quyyumi, Professor of Medicine, Division of Cardiology, Department of Medicine, Emory University School of Medicine, and Co-Director of the Emory Clinical Cardiovascular Research Institute to Serve…

OICR invites applications for the Cancer Therapeutics Innovation Pipeline Program

04/01/2025

“The Cancer Therapeutics Innovation Pipeline (CTIP) Program was established to capitalize on Ontario’s expertise in cancer biology and drug discovery. Its aim is to create a pipeline of validated cancer targets and First-in-Class (FiC) or Best-in-Class (BiC), novel, selective lead molecules (small molecules or biologics) that will attract partnerships and/or investment for further preclinical and…